Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alessandrino, Emilio Paolo, Porta, Matteo G Della, Malcovati, Luca, Jackson, Christopher H, Pascutto, Cristiana, Bacigalupo, Andrea, Teresa van Lint, Maria, Falda, Michele, Bernardi, Massimo, Onida, Francesco, Guidi, Stefano, Iori, Anna Paola, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Angelucci, Emanuele, Oneto, Rosi, Ripamonti, Francesco, Rambaldi, Alessandro, Bosi, Alberto, Cazzola, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736162/
https://www.ncbi.nlm.nih.gov/pubmed/23606215
http://dx.doi.org/10.1002/ajh.23458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736162/
https://www.ncbi.nlm.nih.gov/pubmed/23606215
http://dx.doi.org/10.1002/ajh.23458

Ejemplares similares